InvivoSciences’ CEO/Co-Founder, Ayla Annac, has been invited to speak at the 2016 Biotech and The Law Global Conference & Expo. Her presentation, “Therapeutic Advancement: Developing Drug Discovery Platforms,” will discuss InvivoSciences’ continuing role in the development of precision medicine, particularly the impact of our 3D human tissue model systems on toxicity studies. She will be presenting on…
InvivoSciences was featured in the October 2015 issue of MedTech Dealmakers. The article is titled “Predicting Cardiotoxicity with Engineereed 3D Human Cardiac Tissue Models.” InvivoSciences harnesses human induced pluripotent stem cells to generate patient-specific disease models for drug and diagnostics development.